Narendranath Epperla, MD, MS, discusses the implications of a potential FDA approval for the combination of ublituximab and umbralisib for patients with chronic lymphocytic leukemia.
Narendranath Epperla, MD, MS, a hematologist specializing in the treatment of Hodgkin and non-Hodgkin lymphomas at The Ohio State University Comprehensive Cancer Center—James, discusses the implications of a potential FDA approval for the combination of ublituximab (TGTX-1101) and umbralisib (Ukoniq) for patients with chronic lymphocytic leukemia (CLL).
The approval of this combination would be important, as it would add to the growing armamentarium of agents for the treatment of CLL, according to Epperla. As CLL is an indolent disease, and patients will eventually relapse, having another therapy will be a helpful development, he explains. Having ublituximab and umbralisibavailable in clinical practice for the treatment of patients with CLL will be an exciting prospect, Epperla concludes.